Published in Nat Rev Endocrinol on June 01, 2009
Which risk engines are best to assess CVD risk in diabetes? Nat Rev Endocrinol (2010) 0.75
Does insulin resistance drive the association between hyperglycemia and cardiovascular risk? PLoS One (2012) 0.75
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort. Diabetes Care (2008) 1.70
Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes. Diabetologia (2008) 0.88
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet (2009) 10.55
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med (2010) 7.49
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology (2010) 4.43
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood. Circulation (2010) 4.12
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
Serum chloride is an independent predictor of mortality in hypertensive patients. Hypertension (2013) 3.33
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab (2002) 2.80
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2008) 2.75
Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol (2006) 2.70
Associations of gestational weight gain with maternal body mass index, waist circumference, and blood pressure measured 16 y after pregnancy: the Avon Longitudinal Study of Parents and Children (ALSPAC). Am J Clin Nutr (2011) 2.67
Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care (2008) 2.66
Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis (2012) 2.54
Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation (2012) 2.54
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol (2007) 2.45
Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging (2011) 2.43
B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation (2009) 2.37
A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol (2003) 2.37
The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited) -- a prospective population-based study. J Am Coll Cardiol (2013) 2.36
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24
Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med (2011) 2.24
Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care (2009) 2.23
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart (2011) 2.17
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care (2013) 2.07
Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension (2004) 1.92
Associations between dietary fiber and inflammation, hepatic function, and risk of type 2 diabetes in older men: potential mechanisms for the benefits of fiber on diabetes risk. Diabetes Care (2009) 1.86
Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst (2012) 1.83
Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role? J Am Coll Cardiol (2011) 1.80
Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res (2010) 1.80
Type 2 diabetes and cardiovascular disease in South Asians. Prim Care Diabetes (2010) 1.78
Inflammation and ischaemic stroke. Curr Opin Neurol (2007) 1.77
Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab (2005) 1.74
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) (2008) 1.73
Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. Eur Heart J (2010) 1.73
Childhood obesity and vascular phenotypes: a population study. J Am Coll Cardiol (2012) 1.72
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J (2011) 1.71
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J (2010) 1.69
Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med (2012) 1.69
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
Early emergence of ethnic differences in type 2 diabetes precursors in the UK: the Child Heart and Health Study in England (CHASE Study). PLoS Med (2010) 1.68
Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis (2004) 1.66
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J (2011) 1.66
The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum (2011) 1.63
Adipokines and risk of type 2 diabetes in older men. Diabetes Care (2007) 1.63
High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol (2010) 1.62
Maternal adiposity--a determinant of perinatal and offspring outcomes? Nat Rev Endocrinol (2012) 1.62
Genetic variation at the SLC23A1 locus is associated with circulating concentrations of L-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. Am J Clin Nutr (2010) 1.61
Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index. Int J Epidemiol (2011) 1.61
Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension (2003) 1.60
Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol (2008) 1.59
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) (2008) 1.59
IQ, educational attainment, memory and plasma lipids: associations with apolipoprotein E genotype in 5995 children. Biol Psychiatry (2011) 1.59
The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol (2011) 1.58
Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med (2007) 1.57
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol (2015) 1.57
Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J (2007) 1.55
ABC of obesity. Obesity--time to wake up. BMJ (2006) 1.55
Changes in booking body mass index over a decade: retrospective analysis from a Glasgow Maternity Hospital. BJOG (2005) 1.55
Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. J Clin Endocrinol Metab (2014) 1.55
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J (2012) 1.55
A complex intervention to improve pregnancy outcome in obese women; the UPBEAT randomised controlled trial. BMC Pregnancy Childbirth (2014) 1.55
Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol (2013) 1.54
Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovasc Dis (2011) 1.53
Genetic determinants of metabolic syndrome components in the stroke-prone spontaneously hypertensive rat. J Hypertens (2005) 1.53
Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res (2002) 1.52
Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and obesity in the offspring. Clin Sci (Lond) (2010) 1.50
CVD risk factors and ethnicity--a homogeneous relationship? Atheroscler Suppl (2006) 1.50
Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon Longitudinal Study of Parents and Children. Circulation (2010) 1.49
Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol (2009) 1.47
25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis (2012) 1.46